10% Stockholder Files Intent to Sell Over $1.1M in Shares Following Nasdaq Delisting Notice
TNYA has more than doubled off its 52-week low of $0.36.
Summary
A 10% stockholder intends to sell over $1.1 million in Tenaya Therapeutics shares, a significant transaction occurring shortly after the company received a Nasdaq delisting notice.
Key Events · Ownership and Investor Activity · TNYA
-
Intent to Sell Shares
COLUMN GROUP III, LP, a 10% stockholder, filed a Form 144 to sell 1,408,910 shares of common stock.
-
Significant Transaction Value
The proposed sale has an approximate market value of $1.11 million.
-
Follows Delisting Notice
This intent to sell comes after Tenaya Therapeutics received a Nasdaq delisting notice on January 30, 2026, due to failing to meet the minimum bid price.
Analysis · TNYA · Life Sciences
COLUMN GROUP III, LP, a 10% stockholder, has filed a Form 144 indicating an intent to sell 1,408,910 shares of Tenaya Therapeutics common stock, valued at approximately $1.11 million. This proposed sale represents a notable portion of the company's market capitalization and comes shortly after the company received a Nasdaq delisting notice on January 30, 2026. The timing of this significant insider selling by an institutional investor, amidst the company's struggle to maintain its Nasdaq listing, could signal a lack of confidence and add further downward pressure on the stock.
At the time of this filing, TNYA was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171M. The 52-week trading range was $0.36 to $2.35. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.